AFP Imaging Announces Newtom VGi – The Next Generation CB3D For The ENT And Sleep Apnea Market

February 20, 2009 at 2:00 pm Leave a comment

AFP Imaging Corporation (OTCBB: AFPC.OB) announces the release of the NewTom VGi,
offering the latest technology in the NewTom family of Cone Beam 3D imaging equipment. Officially released in February 2009, the
VGi offers exciting new features including an increased field of view (FOV), improved patient positioning, additional modes with
scan size and resolution options, as well as overall enhanced image quality making it the perfect machine for ENT, Sleep Apnea,
TMJ and other specialty practices. VGi is available in a fixed unit for offices, or in a mobile unit, making a mobile imaging
center an option for any group practice or community.

NewTom VGi, with a 50% larger field of view, captures a full volume of the maxillofacial region providing full cephlometric images
which are vital to ENT’s. The VGi also incorporates a “High Resolution Zoom” mode (HiRes Zoom) that collimates the region of
interest and captures images at twice the resolution of standard scan. The redesigned patient positioning of VGi features a
comfortable motorized chin rest, and positioning lasers. These improvements, in addition to increased patient comfort, stabilize
positioning for clearer and better images.

NewTom CB3D scanners are already the trusted name for producing the clearest 3D images. The new VGi takes quality imaging to
the next level. As an example, when utilizing the VGi’s data with third-party treatment planning software, bone surfaces are less
prone to “holes” in volume reconstructions, a hurdle that other CB3D manufacturers have yet to overcome. The VGi images are
now enhanced with greater contrast and less noise. Artifacts and scatter are negligible, leaving images, including soft tissue views,
remarkably clean allowing ENTs and Sleep Apnea specialists to clearly diagnose issues such as septal deviations, which can
obstruct the nasopharyngeal airway. Pairing NewTom VGi with third party software allows three-dimensional measurement of
airway volume in cubic millimeters from the hard palate to the epiglottis before and after mandibular repositioning, adding a new
dimension to the diagnosis, treatment and patient education for ENTs, TMJ and Sleep Apnea specialists.

“To date, NewTom image quality has been considered the very highest, unsurpassed”, said Roberto Molteni, Chief Technical Officer
for AFP Imaging. “The VGi provides the next generation of imaging excellence for ENT application.”
As with all NewTom products, NewTom VGi includes patented SafeBeam™ technology, which calibrates radiation based on patient
size. Due to the addition of the VGi machines, AFP Imaging is pleased to offer special terms and financing for pre-existing NewTom
models. Contact your AFP/NewTom sales representative at 800-592-6100 now for further details.

About AFP Imaging

AFP Imaging is a state of the art diagnostic imaging supplier whose products are distributed worldwide with clinical applications for
dental, medical and veterinary professionals. For over 30 years, AFP Imaging creates branded products that are installed in over
100,000 dental, medical, ENT and veterinary facilities. The Company’s products are trademarked with brand names that include
AFP, DENT-X, EVA and NEWTOM. For additional corporate information please visit our web site at

The remarks contained in this press release and represented elsewhere by management from time to time contain forward-looking statements,
which involve risks and uncertainties, including statements regarding the Company’s plans, objectives, expectations and intentions. The Company’s
actual results may differ significantly from the results discussed in this press release or in other forward-looking statements presented by
management. Among the factors that could cause actual results to differ materially include the failure of revenue on new products to develop as
estimated, regulatory delays, loss of existing customers, the Company’s continuing default in its senior secured facility, the Company’s inability to
meet increasing demand for its new products, general downward trends in the Company’s industry and other risks as described in the Company’s
filings with the Securities and Exchange Commission. The Company expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in the Company’s expectation or any change in events, conditions or
circumstances on which such statement is based.

AFP Imaging



Entry filed under: Uncategorized.

European Medicines Agency Recommends Suspension Of The Marketing Authorisation Of Raptiva (efalizumab) Focusing On Nanotechnology At American Chemical Society National Meeting, March 22-26

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Top Clicks

  • None

Blog Stats

  • 15,662 hits

%d bloggers like this: